Grant Zeng
Grant Zeng has more than 10 years' professional experience in equity research and analysis. He is currently a senior biotech analyst with Zacks Investment Research Inc., and has been with Zacks since March 2006. Before joining Zacks, Zeng worked for TheStreet.com as a biotech analyst from 2005-2006. From September 2001 to December 2003, Zeng worked for China Pacific Insurance Co. as an equity/fund analyst. Zeng was a healthcare equity analyst with Young & Partners LLC from August 2000 to September 2001. Zeng also has teaching and research experience in pharmaceutical science. Zeng obtained his master's of business administration with a major in finance in 2000 from McMaster University, Canada. He also holds a master's degree in biochemistry from the University of Western Ontario, Canada, and earned a master's degree in pharmacology and bachelor's degree in medicine from Second Military Medical University in China. Zeng is a Chartered Financial Analyst (CFA).
Recent Quotes
"DRRX's total revenue for Q2/18 was $3.4M."
—
Grant Zeng, Zacks Small-Cap Research
(8/6/18)
more >
"For Q4/17, DRRX recorded revenue of $19.5M compared to $3.5M in Q4/16."
—
Grant Zeng, Zacks Small-Cap Research
(3/2/18)
more >
"DRRX's total revenue of $20.7M in Q3/17 compares to $3.7M in Q3/16."
—
Grant Zeng, Zacks Small-Cap Research
(11/2/17)
more >
"We continue to be positive about DRRX's story."
—
Grant Zeng, Zacks Small-Cap Research
(10/25/17)
more >
"We think the patent purchase agreement is a great deal for DRRX."
—
Grant Zeng, Zacks Equity Research
(10/2/17)
more >
"We continue to be optimistic about DRRX's story."
—
Grant Zeng, Zacks Equity Research
(8/10/17)
more >
"We think DRRX and Sandoz' commercialization agreement is a great deal for DRRX."
—
Grant Zeng, Zacks Equity Research
(5/18/17)
more >
"We think this development and commercialization agreement with Sandoz AG is a great deal for DRRX."
—
Grant Zeng, Zacks Equity Research
(5/8/17)
more >
